OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea
· Delayed Price · Currency is KRW 5,940.00
-80.00 (-1.33%)
At close: Mar 31, 2025, 3:30 PM KST
OPTUS Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 81,905 | 72,426 | 58,658 | 57,316 | 60,827 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | Upgrade
|
| Revenue | 81,905 | 72,426 | 58,658 | 57,316 | 60,827 | Upgrade
|
| Revenue Growth (YoY) | 13.09% | 23.47% | 2.34% | -5.77% | 0.64% | Upgrade
|
| Cost of Revenue | 37,277 | 31,072 | 27,041 | 24,821 | 22,531 | Upgrade
|
| Gross Profit | 44,628 | 41,354 | 31,617 | 32,495 | 38,296 | Upgrade
|
| Selling, General & Admin | 32,846 | 30,623 | 24,138 | 20,589 | 21,588 | Upgrade
|
| Research & Development | 1,883 | 1,384 | 1,343 | 1,110 | 821.84 | Upgrade
|
| Other Operating Expenses | 260.69 | 164.19 | 184.49 | 110.92 | 107.83 | Upgrade
|
| Operating Expenses | 36,119 | 33,168 | 26,368 | 22,023 | 23,489 | Upgrade
|
| Operating Income | 8,509 | 8,187 | 5,249 | 10,472 | 14,808 | Upgrade
|
| Interest Expense | -97.24 | -124.4 | -85.89 | -8.88 | -17.61 | Upgrade
|
| Interest & Investment Income | 2,373 | 2,296 | 1,401 | 846.43 | 1,137 | Upgrade
|
| Currency Exchange Gain (Loss) | 84.8 | 3.33 | 12.17 | 127.54 | -17.39 | Upgrade
|
| Other Non Operating Income (Expenses) | -469.62 | 11.79 | 21.69 | -36.76 | 105.62 | Upgrade
|
| EBT Excluding Unusual Items | 10,400 | 10,374 | 6,598 | 11,400 | 16,015 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,242 | 1,967 | 73.39 | - | 2,505 | Upgrade
|
| Gain (Loss) on Sale of Assets | 441.87 | 629.3 | 878.29 | 44.24 | -18.97 | Upgrade
|
| Asset Writedown | - | - | -721.2 | -964.98 | - | Upgrade
|
| Pretax Income | 12,084 | 12,970 | 6,828 | 10,479 | 18,502 | Upgrade
|
| Income Tax Expense | 1,776 | 2,210 | 1,816 | 587.88 | 4,097 | Upgrade
|
| Net Income | 10,308 | 10,760 | 5,012 | 9,892 | 14,405 | Upgrade
|
| Net Income to Common | 10,308 | 10,760 | 5,012 | 9,892 | 14,405 | Upgrade
|
| Net Income Growth | -4.20% | 114.69% | -49.33% | -31.33% | -1.31% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 16 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 16 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | 0.48% | -4.24% | -1.00% | -0.62% | -1.20% | Upgrade
|
| EPS (Basic) | 675.00 | 708.00 | 315.78 | 617.00 | 893.00 | Upgrade
|
| EPS (Diluted) | 675.00 | 708.00 | 315.78 | 617.00 | 893.00 | Upgrade
|
| EPS Growth | -4.66% | 124.21% | -48.82% | -30.91% | -0.11% | Upgrade
|
| Free Cash Flow | -2,903 | 9,109 | -3,955 | -3,557 | 11,603 | Upgrade
|
| Free Cash Flow Per Share | -190.11 | 599.36 | -249.20 | -221.87 | 719.32 | Upgrade
|
| Gross Margin | 54.49% | 57.10% | 53.90% | 56.69% | 62.96% | Upgrade
|
| Operating Margin | 10.39% | 11.30% | 8.95% | 18.27% | 24.34% | Upgrade
|
| Profit Margin | 12.59% | 14.86% | 8.54% | 17.26% | 23.68% | Upgrade
|
| Free Cash Flow Margin | -3.55% | 12.58% | -6.74% | -6.21% | 19.08% | Upgrade
|
| EBITDA | 12,486 | 12,424 | 8,712 | 12,895 | 17,392 | Upgrade
|
| EBITDA Margin | 15.24% | 17.15% | 14.85% | 22.50% | 28.59% | Upgrade
|
| D&A For EBITDA | 3,977 | 4,238 | 3,463 | 2,423 | 2,585 | Upgrade
|
| EBIT | 8,509 | 8,187 | 5,249 | 10,472 | 14,808 | Upgrade
|
| EBIT Margin | 10.39% | 11.30% | 8.95% | 18.27% | 24.34% | Upgrade
|
| Effective Tax Rate | 14.69% | 17.04% | 26.60% | 5.61% | 22.14% | Upgrade
|
| Advertising Expenses | 2,032 | 1,515 | 364.81 | 100.36 | 70.72 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.